Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Mereo BioPharma Group plc (MREO) is a Biotechnology company based in GB with a market capitalization of $48.8M. Free cash flow was negative at -$31M. This page tracks MREO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
GB · 36 employees · IPO Apr 24, 2019
Valuation
Valuation & price
$0.24as of May 17, 2026· -89.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.19
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$48.8M
Market cap
—
Revenue growth (YoY)
73.4%
Gross margin
-$31M
Free cash flow (USD)
-$40.8M
Net debt
Net cash position
7.8%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Mereo BioPharma Group plc's market cap?
Mereo BioPharma Group plc (MREO) has a market capitalization of $48.8M.
What is MREO's P/E ratio?
A meaningful P/E ratio is not available for MREO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is MREO's price-to-book (P/B) ratio?
MREO trades at 1.19 times book value per share.
Are insiders buying MREO stock?
SEC Form 4 filings show no open-market insider buys at Mereo BioPharma Group plc in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.